Medicine has long relied on universal solutions: one treatment, one material, one protocol designed to work for everyone. But according to the EPIBIOMAT (Epibiocompatible Materials for Medicine) research team, the future of healthcare may look very different. Researchers increasingly believe that medicine should be designed not around the “average patient,” but around the biological uniqueness of each individual.
This idea lies at the center of EPIBIOMAT’s work on personalized medicine and advanced biomaterials. The team focuses on developing materials that do not simply exist inside the body as passive structures, but actively interact with biological systems. As the leader of the team, Prof. Beata Kaczmarek-Szczepańska, explains:
What fascinates the EPIBIOMAT team most is the possibility of creating materials that actively interact with the biological environment instead of functioning only as passive structures. — Prof. Kaczmarek-Szczepańska
For decades, medicine relied largely on standardized therapeutic approaches because they were the most accessible and clinically manageable solutions. Yet modern research increasingly demonstrates that the human body is far more individual and complex than previously assumed. Genetics, immune responses, microbiome composition, age and disease progression all influence how patients respond to treatment. As a result, therapies that work effectively for one person may produce entirely different outcomes in another.
This growing understanding is one of the reasons why personalized medicine is becoming one of the major challenges of contemporary healthcare. According to the EPIBIOMAT team, personalized approaches can improve treatment effectiveness, reduce side effects and significantly enhance patients’ quality of life.
Equally as important is the concept of epibiocompatibility. Rather than focusing solely on whether a material is compatible with human tissues, the concept emphasizes dynamic interactions between biomaterials and the body’s biological microenvironment — including cells, microbiota and immune responses. The goal is to create materials that are safer, more adaptive and better integrated with the body’s natural processes.
Advances in biomaterials research may make now-futuristic treatments our reality. The patient experience may actually be improved thanks to wound dressings capable of responding to inflammation, bioactive hydrogels supporting tissue regeneration, personalized implants, antimicrobial surfaces and targeted drug-delivery systems. And these are just a few examples of the many possible outcomes of the project.
Prof. Kaczmarek-Szczepańska stresses that “EPIBIOMAT is trying to help create a future in which medical materials are intelligent, sustainable, and adapted to patient-specific biological needs and are developed responsibly with respect to both people and the environment.” Future medical technologies must respect not only human biology, but also the environment – this approach opens the door to working on natural polymers, green chemistry and biodegradable systems that use environmental resources responsibly.
The EPIBIOMAT team is proud of developing innovative biomaterials combining regenerative, antioxidant and antimicrobial properties while building a strong interdisciplinary research environment connecting fundamental science with practical biomedical applications. With this being only the beginning, the possible future outcomes seem extremely transformative.
